First Case with Catalyst OrthoScience Archer R1 Reverse Shoulder

Catalyst OrthoScience announced the first surgeries using the new Archer™ R1 Reverse Shoulder. Limited launch is underway, and commercial launch is slated for later in the year.

Catalyst gained FDA 510(k) clearance for the system in 1Q21. With its introduction, Catalyst is addressing two rapidly growing segments of the shoulder arthroplasty market – stemless anatomic and reverse total shoulder replacement.

Archer R1 reverse is a single-tray system that was engineered to combine the most beneficial and evidence-based attributes of reverse shoulder arthroplasty design. It offers surgeon-targeted implant positioning, a streamlined and versatile system and bone sparing implants. It features a stemless, ellipsoid humeral component that is engineered to accurately replace the elliptical shape of the patient’s native non-spherical ​humeral head.

“Reverse shoulder arthroplasty encompasses more than 60% of the shoulder arthroplasty market,” said Brian K. Hutchison, Chairman and CEO of Catalyst. “These first surgeries with our Archer R1 reverse system went well, and we’re excited by the feedback we’re getting from the initial surgeon users.”